Positive News SentimentPositive NewsNASDAQ:ACXP Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis $2.01 -0.03 (-1.47%) (As of 02:37 PM ET) Add Compare Share Share Today's Range$1.99▼$2.0350-Day Range$1.87▼$2.6252-Week Range$1.17▼$8.82Volume11,709 shsAverage Volume102,183 shsMarket Capitalization$31.84 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Acurx Pharmaceuticals alerts: Email Address Acurx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside497.0% Upside$12.00 Price TargetShort InterestBearish3.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.98) to ($2.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.87 out of 5 starsMedical Sector626th out of 927 stocksPharmaceutical Preparations Industry288th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingAcurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Acurx Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.29% of the float of Acurx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently increased by 3.05%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAcurx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcurx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACXP. Previous Next 3.3 News and Social Media Coverage News SentimentAcurx Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Acurx Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for ACXP on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows1 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders35.30% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.53% of the stock of Acurx Pharmaceuticals is held by institutions.Read more about Acurx Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acurx Pharmaceuticals are expected to decrease in the coming year, from ($0.98) to ($2.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acurx Pharmaceuticals is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acurx Pharmaceuticals is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcurx Pharmaceuticals has a P/B Ratio of 5.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Acurx Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> About Acurx Pharmaceuticals Stock (NASDAQ:ACXP)Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Read More ACXP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACXP Stock News HeadlinesAugust 26, 2024 | prnewswire.comACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment ConferenceAugust 25, 2024 | uk.finance.yahoo.comWe're A Little Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn RateSeptember 16, 2024 | DTI (Ad)Ever heard of this 8-day bitcoin profit window? Did you know Bitcoin almost always soars higher during This 8-Day Profit Window? And when I say almost always… I really mean it. For over a year now, traders have had the chance to cash in during this time with an 83% success rate using these New Bitcoin Options. Now of course I can’t promise future returns or against losses…August 15, 2024 | investing.comAcurx Pharmaceuticals LLC (ACXP)August 10, 2024 | markets.businessinsider.comIbezapolstat’s Strategic Advancements and Market Potential Bolster Buy Rating for Acurx PharmaceuticalsAugust 10, 2024 | insidermonkey.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business UpdateJuly 17, 2024 | prnewswire.comUSPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut MicrobiomeSeptember 16, 2024 | DTI (Ad)Ever heard of this 8-day bitcoin profit window? Did you know Bitcoin almost always soars higher during This 8-Day Profit Window? And when I say almost always… I really mean it. For over a year now, traders have had the chance to cash in during this time with an 83% success rate using these New Bitcoin Options. Now of course I can’t promise future returns or against losses…July 16, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business UpdateJuly 15, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific ConferenceMay 17, 2024 | seekingalpha.comAcurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call TranscriptMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acurx Pharmaceuticals Amid Promising CDI Drug Candidate Progress and Solid FinancialsMay 16, 2024 | insidermonkey.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finance.yahoo.comAcurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ...May 16, 2024 | finance.yahoo.comQ1 2024 Acurx Pharmaceuticals Inc Earnings CallMay 15, 2024 | morningstar.comAcurx Pharmaceuticals Inc Ordinary SharesMay 15, 2024 | msn.comAcurx Pharmaceuticals GAAP EPS of -$0.28 misses by $0.04See More Headlines Receive ACXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today9/16/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACXP CUSIPN/A CIK1736243 Webwww.acurxpharma.com Phone917-533-1469FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+482.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-371.20% Return on Assets-219.01% Debt Debt-to-Equity RatioN/A Current Ratio2.09 Quick Ratio2.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book6.06Miscellaneous Outstanding Shares15,843,000Free Float10,250,000Market Cap$32.64 million OptionableOptionable Beta-1.72 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Robert J. DeLuccia (Age 78)Co-Founder & Executive Chairman Comp: $701.54kMr. David P. Luci CPA (Age 57)Esq., J.D., Co-Founder, President, CEO, Corporate Secretary & Director Comp: $668.98kMr. Robert G. Shawah CPA (Age 57)CPA, Co-Founder & CFO Comp: $470.29kKey CompetitorsAytu BioPharmaNASDAQ:AYTUIndaptus TherapeuticsNASDAQ:INDPAgile TherapeuticsNASDAQ:AGRXKodiak SciencesNASDAQ:KODAdageneNASDAQ:ADAGView All CompetitorsInstitutional OwnershipProspect Financial Services LLCBought 5,250 shares on 7/15/2024Ownership: 1.756%View All Institutional Transactions ACXP Stock Analysis - Frequently Asked Questions How have ACXP shares performed this year? Acurx Pharmaceuticals' stock was trading at $3.83 at the beginning of 2024. Since then, ACXP shares have decreased by 47.5% and is now trading at $2.01. View the best growth stocks for 2024 here. How were Acurx Pharmaceuticals' earnings last quarter? Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) issued its quarterly earnings data on Friday, August, 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. When did Acurx Pharmaceuticals IPO? Acurx Pharmaceuticals (ACXP) raised $15 million in an IPO on Friday, June 25th 2021. The company issued 2,500,000 shares at a price of $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO. Who are Acurx Pharmaceuticals' major shareholders? Top institutional shareholders of Acurx Pharmaceuticals include Prospect Financial Services LLC (1.76%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia. View institutional ownership trends. How do I buy shares of Acurx Pharmaceuticals? Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACXP) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.